Arkolith/Insider Trading/LXEO/Form 4

See Tai Sandi

Chief Development OfficerLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Nov 20, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 18, 2025Sell(S)386$9.27$4K65K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002009350-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML